Prestige BioPharma Limited (KRX:950210)

Prestige BioPharma Ratios and Metrics

Market cap in millions KRW. Fiscal year is July - June.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 4, 2025	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Market Capitalization	164,303	176,683	103,966	113,582	137,620	396,635
Market Cap Growth	-24.06%	69.94%	-8.47%	-17.47%	-65.30%	-
Enterprise Value	246,963	210,197	44,042	-6,736	-150,494	-63,944
Last Close Price	13670.00	14700.00	8650.00	9450.00	11450.00	33000.00
PE Ratio	52.10	7.92	-	6.47	-	-
Forward PE	-	12.01	12.01	12.01	12.01	-
PS Ratio	11.40	12.33	150.88	701.81	-	-
PB Ratio	0.33	0.35	0.20	0.21	0.32	0.69
P/TBV Ratio	0.45	0.48	0.26	0.28	0.32	0.69
EV/Sales Ratio	17.14	14.67	63.92	-	-	-
Debt / Equity Ratio	0.25	0.28	0.17	0.21	0.01	0.01
Debt / EBITDA Ratio	-	-	-	9.11	-	-
Asset Turnover	0.02	0.02	0.00	0	-	-
Inventory Turnover	0.94	1.18	0.89	0.01	-	-
Quick Ratio	0.92	1.05	1.53	2.24	7.26	32.70
Current Ratio	1.17	1.27	1.72	2.31	7.46	32.74
Return on Equity (ROE)	-1.07%	0.81%	-10.38%	-0.59%	-42.08%	-2.07%
Return on Assets (ROA)	-6.58%	-5.71%	-5.35%	0.10%	-13.89%	-3.01%
Return on Capital (ROIC)	-7.69%	-6.62%	-6.14%	0.12%	-15.08%	-3.18%
Return on Capital Employed (ROCE)	-13.30%	-11.50%	-11.00%	0.20%	-26.80%	-3.10%
Earnings Yield	9.59%	12.62%	-31.66%	15.47%	-153.65%	-1.86%
FCF Yield	-45.77%	-52.57%	-65.49%	-95.65%	-74.36%	-4.13%
Buyback Yield / Dilution	0.20%	-0.44%	0.22%	-	-16.46%	-20.98%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.